Physician profile
Alicia Chen
NPI 1598772873
$2,939.14
in general payments reported to CMS, 2019-2025
29 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $385 · 2021: $375 · 2022: $634 · 2023: $198 · 2024: $389 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.94 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $323.71 | 2019-2022 | |
| Amgen INC. | $305.11 | 2020-2025 | Evenity, Repatha |
| Abbvie INC. | $272.48 | 2019-2023 | Ubrelvy |
| Lilly USA, LLC | $213.52 | 2019-2023 | Jardiance |
| Regeneron Pharmaceuticals, INC. | $146.88 | 2024 | Eylea Hd |
| Amarin Pharma, INC. | $137.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $137.25 | 2019-2023 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.25 | 2019-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $112.81 | 2021-2024 | Nexletol |
| Organogenesis INC. | $108.25 | 2022 | |
| Abbott Laboratories | $104.88 | 2021-2024 | Freestyle Libre 2, Infinity, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $104.84 | 2021-2024 | |
| Pfizer INC. | $97.84 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.75 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $43.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $41.21 | 2020 | |
| Sanofi-Aventis U.S. LLC | $38.09 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.39 | 2021 | |
| Radius Health, INC. | $19.30 | 2020 | |
| Axsome Therapeutics, INC. | $18.51 | 2024 | Sunosi |
| Astellas Pharma US INC | $17.84 | 2019 | |
| Allergan, INC. | $17.66 | 2020 | |
| Philips North America LLC | $17.04 | 2024 | (Ak6) Vest Therapy |
| Alexion Pharmaceuticals, INC. | $15.58 | 2021 | |
| Alfasigma USA, INC. | $14.99 | 2022 | |
| Eisai INC. | $13.24 | 2021 | |
| Genentech USA, INC. | $12.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.